Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer

Authors

• M S. Brose

Publication/Presentation Date

10-2023

Volume

34

Issue

2

First Page

1338

Last Page

1338

Published In/Presented At

https://doi.org/10.1016/j.annonc.2023.10.103

Disciplines

Medicine and Health Sciences

Department(s)

Hematology-Medical Oncology Division

Document Type

Article